

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8194397

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SRX CARDIO, LLC	12/30/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PORTOLA PHARMACEUTICALS, INC.
<b>Street Address:</b>	270 E. GRAND AVE
<b>Internal Address:</b>	SUITE 22
<b>City:</b>	SOUTH SAN FRANCISCO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94080
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17020276
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	1650815260
<b>Email:</b>	sdieu@sheppardmullin.com
<b>Correspondent Name:</b>	SHEPPARD MULLIN RICHTER & HAMPTON LLP
<b>Address Line 1:</b>	650 TOWN CENTER DRIVE, 10TH FLOOR
<b>Address Line 4:</b>	COSTA MESA, CALIFORNIA 92626-1993
<b>ATTORNEY DOCKET NUMBER:</b>	69TJ-267795-US2
<b>NAME OF SUBMITTER:</b>	YOUNG CHANG
<b>SIGNATURE:</b>	/Young Chang/
<b>DATE SIGNED:</b>	09/28/2023
<b>Total Attachments: 3</b>	
source=Executed PCT Assignment SRX to Portola_69TJ-267795-US2#page1.tif	
source=Executed PCT Assignment SRX to Portola_69TJ-267795-US2#page2.tif	
source=Executed PCT Assignment SRX to Portola_69TJ-267795-US2#page3.tif	

**ASSIGNMENT-WORLDWIDE**  
(Patent Application)


For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, SRX CARDIO, LLC (hereinafter referred to as "Assignor"), a corporation having a principal place of business at 732 Pittsford-Victor Road, Pittsford, NY 14534, is an owner by way of assignment from named inventors, of the right, title and interest in an to the inventions directed to:

Atty. Dkt No.	Country	Appl. No.	Filing Date	Title
18405	PCT	PCT/US2016/047798	08/19/2016	Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity
18406	PCT	PCT/US2016/047810	08/19/2016	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity
18407	PCT	PCT/US2016/047816	08/19/2016	Composition and Methods of Use of Phenylpiperazine Compounds that Bind and Modulate Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Activity

1. Assignor agrees to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to PORTOLA PHARMACEUTICALS, INC., having a principal place of business at 270 E. Grand Ave., Suite 22, South San Francisco, CA 94080 ("Assignee"), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;

- (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisional, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
  - (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. § 154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside our signature.

Signature:   
SIX Cardio, LLC  
Name: Kyle D. Hume  
Title: CEO, LLC Manager

Date: 12/30/16

Assignment received and accepted by Assignee:

Signature:   
Ting Su, Director Intellectual Property

Date: 1/10/2017